A Study of CLR325 in Chronic Stable Heart Failure Patients.

Status Completed

Clinical Trial Summary

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02696967
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	May 17, 2016
Completion date	January 14, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03346278` - Text Message Intervention to Improve Cardiac Rehab Participation	N/A
Recruiting	`NCT03834155` - Enhancing Cardiac Rehabilitation Through Behavioral Nudges	N/A
Withdrawn	`NCT04507347` - Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus	Phase 3
Completed	`NCT02204449` - Cardiac Rehabilitation Peer Mentorship	N/A
Completed	`NCT00663195` - Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure	Phase 4
Completed	`NCT00664222` - Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)	Phase 4
Completed	`NCT00663494` - Matrix Metalloproteinase (MMP) in Heart Failure	N/A
Recruiting	`NCT05034549` - Noninvasive Ventilation for Chronic Heart Failure	N/A
Recruiting	`NCT01065194` - Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure	Phase 3